Evidence map›Paper›PMID 36354585›Full record

ArticleBioengineering (Basel, Switzerland)2022

Droplet Microfluidics Enables Tracing of Target Cells at the Single-Cell Transcriptome Resolution.

Yang Liu, Shiyu Wang, Menghua Lyu, Run Xie, Weijin Guo, Ying He, Xuyang Shi, Yang Wang, Jingyu Qi, Qianqian Zhu and 10 more

Open access · goldAbstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

Yang LiuBGI-Shenzhen, Shenzhen 518083, China.
Shiyu WangBGI-Shenzhen, Shenzhen 518083, China.ORCID 0000-0001-8851-1697
Menghua LyuBGI-Shenzhen, Shenzhen 518083, China.
Run XieDepartment of Biomedical Engineering, School of Medicine, Shenzhen University, Shenzhen 518060, China.
Weijin GuoDepartment of Biomedical Engineering, Shantou University, Shantou 515063, China.ORCID 0000-0003-2444-6771
Ying HeDepartment of Gynaecological Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen 518116, China.ORCID 0000-0002-9881-8155
Xuyang ShiBGI-Shenzhen, Shenzhen 518083, China.
Yang WangBGI-Shenzhen, Shenzhen 518083, China.
Jingyu QiBGI-Shenzhen, Shenzhen 518083, China.
Qianqian ZhuBGI-Shenzhen, Shenzhen 518083, China.ORCID 0000-0002-3867-4954
Hui ZhangBGI-Shenzhen, Shenzhen 518083, China.
Tao LuoDepartment of Mechanical & Electrical Engineering, Xiamen University, Xiamen 361101, China.ORCID 0000-0002-4861-3397
Huaying ChenSchool of Mechanical Engineering and Automation, Harbin Institute of Technology, Shenzhen, Shenzhen 518055, China.
Yonggang ZhuSchool of Mechanical Engineering and Automation, Harbin Institute of Technology, Shenzhen, Shenzhen 518055, China.ORCID 0000-0002-5419-9508
Xuan DongBGI-Shenzhen, Shenzhen 518083, China.ORCID 0000-0001-8288-322X
Zida LiDepartment of Biomedical Engineering, School of Medicine, Shenzhen University, Shenzhen 518060, China.ORCID 0000-0002-1353-9414
Ying GuBGI-Shenzhen, Shenzhen 518083, China.
Longqi LiuBGI-Shenzhen, Shenzhen 518083, China.
Xun XuBGI-Shenzhen, Shenzhen 518083, China.
Ya LiuBGI-Shenzhen, Shenzhen 518083, China.ORCID 0000-0002-3936-1685
BGI Group (China) · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNHarbin Institute of Technology · CNShenzhen University · CNXiamen University · CN

Funding

Guangdong Basic and Applied Basic Research Foundation 2021A1515110459National Key Research and Development Program of China 2021YFF1200500Shantou University Scientific Research Foundation for Talents NTF20034
6 · The paper itself

Abstract

The rapid promotion of single-cell omics in various fields has begun to help solve many problems encountered in research, including precision medicine, prenatal diagnosis, and embryo development. Meanwhile, single-cell techniques are also constantly updated with increasing demand. For some specific target cells, the workflow from droplet screening to single-cell sequencing is a preferred option and should reduce the impact of operation steps, such as demulsification and cell recovery. We developed an all-in-droplet method integrating cell encapsulation, target sorting, droplet picoinjection, and single-cell transcriptome profiling on chips to achieve labor-saving monitoring of TCR-T cells. As a proof of concept, in this research, TCR-T cells were encapsulated, sorted, and performed single-cell transcriptome sequencing (scRNA-seq) by injecting reagents into droplets. It avoided the tedious operation of droplet breakage and re-encapsulation between droplet sorting and scRNA-seq. Moreover, convenient device operation will accelerate the progress of chip marketization. The strategy achieved an excellent recovery performance of single-cell transcriptome with a median gene number over 4000 and a cross-contamination rate of 8.2 ± 2%. Furthermore, this strategy allows us to develop a device with high integrability to monitor infused TCR-T cells, which will promote the development of adoptive T cell immunotherapy and their clinical application.

Indexed as

droplet-based microfluidicsdroplet picoinjectionsingle-cell transcriptomeT-cell

Identifiers

PMID36354585
PMCPMC9687293
OpenAlexW4308769514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.